Study analysis · Molecules · 2026
Olive leaf extract beat a diabetes drug in lab tests — but that doesn't mean it treats diabetes in humans.
A review of lab-dish studies found olive and pomegranate compounds can block enzymes tied to inflammation, blood sugar, Alzheimer's, and drug metabolism, but there's no proof yet that eating them changes human disease risk.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is a big summary of lab experiments done in test tubes, not in people. It shows that certain plant compounds can block some enzymes in the lab, which might be a clue for future medicine. But it doesn't prove that eating olives or pomegranates will prevent or treat any disease in humans.
What’s the bottom line?
Scientists reviewed many laboratory experiments on olive and pomegranate polyphenols. In test tubes, these compounds blocked enzymes linked to inflammation, blood sugar, Alzheimer’s disease, and drug metabolism. But the review did not test people, so it cannot prove these foods treat or prevent any disease.
How strong is this study?
The researchers did a good job searching for studies and following a standard checklist. But the lab experiments they found were very different from each other, and they couldn't combine the numbers. So the summary is useful for scientists, but we shouldn't trust it as proof that these foods work in our bodies.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. In vitro studies cannot establish causation in humans. Enzyme inhibition in laboratory assays does not account for bioavailability, metabolism, tissue distribution, or clinical outcomes. No human or animal data are included, so causal links to disease prevention or treatment cannot be inferred.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statements were identified in the provided text, but the article appears truncated before any declaration sections, so COI status cannot be fully determined.
The provided text is a systematic review and is cut off mid-sentence in section 3; no COI, funding, or author affiliation sections are included. Therefore, COI/funding status cannot be fully verified from the available text.
Key takeaways
- 01
In lab tests, olive leaf extract blocked α-amylase with IC50 0.75 µg/mL, while acarbose was 15.74 µg/mL.
- 02
Luteolin blocked α-glucosidase with IC50 0.4 µg/mL.
- 03
Pomegranate seed extract blocked AChE by up to 67.8% and BChE by up to 79.8%.
- 04
Punicalagin and ellagic acid blocked β-secretase at IC50 4.1×10−7 M and 3.9×10−6 M.
- 05
These are in vitro numbers, not human relative or absolute risk reductions.
- 06
This study did not measure people, so it cannot tell you how many extra cases of diabetes, Alzheimer’s, or inflammation are prevented or caused.
- 07
The absolute clinical benefit or risk was not reported.
- 08
The lab-dish results only show that these compounds can inhibit enzymes under artificial conditions; they do not prove that eating olives or pomegranate changes human disease risk.
Surprising findings
- Olive leaf extract had ~21-fold lower IC50 than acarbose for α-amylase in vitro (0.75 vs 15.74 µg/mL), meaning it was more potent in that lab assay.A natural extract appearing more potent than a prescription diabetes drug is counterintuitive and often hyped online.
- Solvent changed pomegranate's CYP inhibition from >70–98% to <10%.Same plant material, different extraction, opposite drug-interaction potential. This undermines one-size-fits-all supplement claims.
- The review explicitly says in vitro enzyme inhibition should not be interpreted as clinical efficacy.Even though the abstract lists many benefits, the authors are skeptical about translation.
Practical takeaways
Don't replace prescribed diabetes, Alzheimer's, or anti-inflammatory medications with olive or pomegranate supplements based on this review.
All evidence is in vitro; no human clinical outcomes or absolute risk reductions were reported.
low confidenceIf you take medications with a narrow therapeutic index (e.g., warfarin, some immunosuppressants), ask your doctor or pharmacist before using concentrated pomegranate or olive supplements.
In vitro CYP inhibition was shown, but the clinical magnitude of interactions in humans is unknown.
low confidenceEnjoy olives, olive oil, and pomegranate as part of a Mediterranean-style diet, but don't megadose extracts for unproven disease prevention.
The review does not prove that these foods prevent or treat any disease; benefits may come from overall dietary patterns.
medium confidenceWhen reading supplement claims, look for human outcome data, not just IC50 values or percent inhibition.
Lab-dish potency can be misleading because bioavailability, metabolism, and assay conditions vary widely.
high confidenceWhy this study matters
Lab-dish potency vs human reality
In vitro, olive leaf extract inhibited α-amylase with IC50 0.75 µg/mL, while acarbose was 15.74 µg/mL — about 21-fold lower IC50 (relative in vitro potency). But the review reports no human absolute risk reduction for diabetes or any clinical outcome.
People see '21x stronger than diabetes drug' and assume it works in the body. The review explicitly warns these are lab assays, not clinical effects.
Pomegranate's enzyme-blocking cocktail
Pomegranate seed extract inhibited AChE by up to 67.8% and BChE by up to 79.8% in vitro. Punicalagin and ellagic acid inhibited β-secretase with IC50 values of 4.1×10⁻⁷ M and 3.9×10⁻⁶ M, respectively. These are lab enzyme assays, not memory or Alzheimer's outcomes.
Alzheimer's is scary, and these numbers look drug-like. But no human cognition or disease progression was measured.
Hidden drug-interaction risk
In vitro, a methanolic pomegranate fraction inhibited CYP2D6 by 98.1% and CYP3A4 by >70%, while ethanolic extracts inhibited both by <10%. Olive oleuropein inhibited CYP3A-mediated androstenedione β-hydroxylase by 42% and CYP1A2 by 24%. The clinical magnitude of these herb–drug interactions in humans is unknown.
Many people take pomegranate or olive supplements with prescription drugs. This raises a red flag, though the real-world effect is unmeasured.
One plant, many targets — but no clinical proof
The review compiled 57 in vitro studies showing olive and pomegranate polyphenols inhibit COX, LOX, AChE, BChE, BACE1, α-amylase, α-glucosidase, and CYP450. The authors conclude translation is limited by unknown bioavailability, metabolism, and blood-brain barrier penetration.
It sounds like a miracle multi-target compound, but the same review says we can't jump from test tubes to treatments.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists reviewed many laboratory experiments on olive and pomegranate polyphenols. In test tubes, these compounds blocked enzymes linked to inflammation, blood sugar, Alzheimer’s disease, and drug metabolism. But the review did not test people, so it cannot prove these foods treat or prevent any disease.
Research results
In lab tests, olive leaf extract blocked α-amylase with IC50 0.75 µg/mL, while acarbose was 15.74 µg/mL. Luteolin blocked α-glucosidase with IC50 0.4 µg/mL. Pomegranate seed extract blocked AChE by up to 67.8% and BChE by up to 79.8%. Punicalagin and ellagic acid blocked β-secretase at IC50 4.1×10−7 M and 3.9×10−6 M. These are in vitro numbers, not human relative or absolute risk reductions.
What this means - more context
This study did not measure people, so it cannot tell you how many extra cases of diabetes, Alzheimer’s, or inflammation are prevented or caused. The absolute clinical benefit or risk was not reported. The lab-dish results only show that these compounds can inhibit enzymes under artificial conditions; they do not prove that eating olives or pomegranate changes human disease risk.
Systematic review of in vitro studies on enzyme inhibition by olive (Olea europaea L.) and pomegranate (Punica granatum L.) polyphenols, covering inflammatory, carbohydrate-metabolizing, neuroprotective, and drug-metabolizing enzyme systems. No retraction or corrections reported in Crossref/PubMed.
This PRISMA systematic review compiled 57 in vitro studies and found that olive and pomegranate polyphenols inhibit COX, LOX, AChE, BChE, BACE1, α-amylase, α-glucosidase, and CYP450 enzymes in laboratory assays. However, it explicitly cautions that these are in vitro IC50/percentage-inhibition findings, not clinical outcomes. No human absolute risk or benefit estimates were reported. Translation is limited by unknown bioavailability, metabolism, blood-brain barrier penetration, and clinical magnitude of herb-drug interactions.
Methods Used
PRISMA-guided search of PubMed and Web of Science up to 15 April 2026 using olive/pomegranate and enzyme-inhibition keywords. From 1000 records, 499 remained after duplicate removal, 177 full texts were assessed, and 57 in vitro studies were included. Narrative synthesis only; no meta-analysis due to heterogeneity in enzyme sources, substrates, extraction methods, IC50 units, and assay conditions.
Main Finding
In vitro, olive and pomegranate polyphenols inhibited multiple enzymes. Examples include oleocanthal inhibiting COX-1/COX-2; olive leaf extract inhibiting α-amylase with IC50 0.75 µg/mL versus acarbose IC50 15.74 µg/mL; luteolin inhibiting α-glucosidase with IC50 0.4 µg/mL; pomegranate seed extract inhibiting AChE by up to 67.8% and BChE by up to 79.8%; punicalagin and ellagic acid inhibiting β-secretase with IC50 4.1×10−7 M and 3.9×10−6 M. These are laboratory potencies, not relative or absolute clinical effects. The review does not demonstrate clinical efficacy for diabetes, Alzheimer’s disease, or inflammatory conditions, and no human absolute risk reduction was reported.
Confidence Level
Low for clinical translation because all evidence is in vitro and clinical outcomes were not assessed. Moderate confidence in the pattern of in vitro enzyme inhibition, but high methodological heterogeneity, lack of meta-analysis, and incomplete bioavailability/BBB/CYP interaction data limit certainty.
Study Flags
Red Flags
- •In vitro only; no in vivo or clinical validation
- •High methodological heterogeneity prevented meta-analysis
- •Bioavailability, metabolism, blood-brain barrier penetration, and clinical magnitude of CYP interactions remain unknown
Surprising Findings
Olive leaf extract had ~21-fold lower IC50 than acarbose for α-amylase in vitro (0.75 vs 15.74 µg/mL), meaning it was more potent in that lab assay.
A natural extract appearing more potent than a prescription diabetes drug is counterintuitive and often hyped online.
Practical Takeaways
Don't replace prescribed diabetes, Alzheimer's, or anti-inflammatory medications with olive or pomegranate supplements based on this review.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Systematic Review
Subject
Lower probability
on the GRADE evidence scale
This study is a big summary of lab experiments done in test tubes, not in people. It shows that certain plant compounds can block some enzymes in the lab, which might be a clue for future medicine. But it doesn't prove that eating olives or pomegranates will prevent or treat any disease in humans.
Strengths
- Followed PRISMA guidelines
- Systematic search of PubMed and Web of Science
- Included quality assessment criteria
Weaknesses
- Only in vitro studies included
- High methodological heterogeneity precluded meta-analysis
- No formal risk of bias tool applicable
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists reviewed many laboratory experiments on olive and pomegranate polyphenols. In test tubes, these compounds blocked enzymes linked to inflammation, blood sugar, Alzheimer’s disease, and drug metabolism. But the review did not test people, so it cannot prove these foods treat or prevent any disease.
Research results
In lab tests, olive leaf extract blocked α-amylase with IC50 0.75 µg/mL, while acarbose was 15.74 µg/mL. Luteolin blocked α-glucosidase with IC50 0.4 µg/mL. Pomegranate seed extract blocked AChE by up to 67.8% and BChE by up to 79.8%. Punicalagin and ellagic acid blocked β-secretase at IC50 4.1×10−7 M and 3.9×10−6 M. These are in vitro numbers, not human relative or absolute risk reductions.
What this means - more context
This study did not measure people, so it cannot tell you how many extra cases of diabetes, Alzheimer’s, or inflammation are prevented or caused. The absolute clinical benefit or risk was not reported. The lab-dish results only show that these compounds can inhibit enzymes under artificial conditions; they do not prove that eating olives or pomegranate changes human disease risk.
Systematic review of in vitro studies on enzyme inhibition by olive (Olea europaea L.) and pomegranate (Punica granatum L.) polyphenols, covering inflammatory, carbohydrate-metabolizing, neuroprotective, and drug-metabolizing enzyme systems. No retraction or corrections reported in Crossref/PubMed.
This PRISMA systematic review compiled 57 in vitro studies and found that olive and pomegranate polyphenols inhibit COX, LOX, AChE, BChE, BACE1, α-amylase, α-glucosidase, and CYP450 enzymes in laboratory assays. However, it explicitly cautions that these are in vitro IC50/percentage-inhibition findings, not clinical outcomes. No human absolute risk or benefit estimates were reported. Translation is limited by unknown bioavailability, metabolism, blood-brain barrier penetration, and clinical magnitude of herb-drug interactions.
Methods Used
PRISMA-guided search of PubMed and Web of Science up to 15 April 2026 using olive/pomegranate and enzyme-inhibition keywords. From 1000 records, 499 remained after duplicate removal, 177 full texts were assessed, and 57 in vitro studies were included. Narrative synthesis only; no meta-analysis due to heterogeneity in enzyme sources, substrates, extraction methods, IC50 units, and assay conditions.
Main Finding
In vitro, olive and pomegranate polyphenols inhibited multiple enzymes. Examples include oleocanthal inhibiting COX-1/COX-2; olive leaf extract inhibiting α-amylase with IC50 0.75 µg/mL versus acarbose IC50 15.74 µg/mL; luteolin inhibiting α-glucosidase with IC50 0.4 µg/mL; pomegranate seed extract inhibiting AChE by up to 67.8% and BChE by up to 79.8%; punicalagin and ellagic acid inhibiting β-secretase with IC50 4.1×10−7 M and 3.9×10−6 M. These are laboratory potencies, not relative or absolute clinical effects. The review does not demonstrate clinical efficacy for diabetes, Alzheimer’s disease, or inflammatory conditions, and no human absolute risk reduction was reported.
Confidence Level
Low for clinical translation because all evidence is in vitro and clinical outcomes were not assessed. Moderate confidence in the pattern of in vitro enzyme inhibition, but high methodological heterogeneity, lack of meta-analysis, and incomplete bioavailability/BBB/CYP interaction data limit certainty.
Study Flags
Red Flags
- •In vitro only; no in vivo or clinical validation
- •High methodological heterogeneity prevented meta-analysis
- •Bioavailability, metabolism, blood-brain barrier penetration, and clinical magnitude of CYP interactions remain unknown
Surprising Findings
Olive leaf extract had ~21-fold lower IC50 than acarbose for α-amylase in vitro (0.75 vs 15.74 µg/mL), meaning it was more potent in that lab assay.
A natural extract appearing more potent than a prescription diabetes drug is counterintuitive and often hyped online.
Practical Takeaways
Don't replace prescribed diabetes, Alzheimer's, or anti-inflammatory medications with olive or pomegranate supplements based on this review.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Systematic Review
Subject
Lower probability
on the GRADE evidence scale
This study is a big summary of lab experiments done in test tubes, not in people. It shows that certain plant compounds can block some enzymes in the lab, which might be a clue for future medicine. But it doesn't prove that eating olives or pomegranates will prevent or treat any disease in humans.
Strengths
- Followed PRISMA guidelines
- Systematic search of PubMed and Web of Science
- Included quality assessment criteria
Weaknesses
- Only in vitro studies included
- High methodological heterogeneity precluded meta-analysis
- No formal risk of bias tool applicable
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did a good job searching for studies and following a standard checklist. But the lab experiments they found were very different from each other, and they couldn't combine the numbers. So the summary is useful for scientists, but we shouldn't trust it as proof that these foods work in our bodies.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 528 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. In vitro studies cannot establish causation in humans. Enzyme inhibition in laboratory assays does not account for bioavailability, metabolism, tissue distribution, or clinical outcomes. No human or animal data are included, so causal links to disease prevention or treatment cannot be inferred.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statements were identified in the provided text, but the article appears truncated before any declaration sections, so COI status cannot be fully determined.
The provided text is a systematic review and is cut off mid-sentence in section 3; no COI, funding, or author affiliation sections are included. Therefore, COI/funding status cannot be fully verified from the available text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Ben Azadi cite this study, drawing 1 claim from it.
- Indication only
Weak evidence — fewer than 20 studies, so treat this as a starting point, not a fact.
Evidence
Authored by
5 researchersIf this is your work, this is how we attribute it on Fit Body Science. Robert Vučina is listed as the lead author.